KPSGILL Enforcement Watch · Published · Enforcement record through · site record current through
This ledger’s own source check runs to 31 August 2026. The site snapshot of 1 September does not imply that every tracker was independently re-read at that instant.
Enforcement Watch
Government actions in health care are not interchangeable. An indictment, a civil settlement, a board accusation, an inspector-general audit and a proposed rule are five different kinds of act, and a page that stacks them together without saying so misleads the reader about what has actually been decided. Every record here carries its action type, its lifecycle state, the deciding body, the authority cited, the date, and the disposition.
Representative illustration · not real people, institutions or events.
How records are classified
CRIMINAL CHARGE
An indictment, information or complaint. An allegation only. No finding of guilt exists until conviction or plea, and a charge later dismissed is recorded as dismissed on the same record rather than deleted.
CIVIL SETTLEMENT
A negotiated resolution, ordinarily with no admission of liability. The settlement amount is not a measure of proven harm and is never reported as a fine or a finding.
ADMINISTRATIVE ENFORCEMENT
An agency action under its own statute — a licensing board accusation or decision, a plan penalty, a corrective action plan. The deciding body, the authority cited and the disposition all belong in the record.
AUDIT / OVERSIGHT FINDING
An inspector-general, GAO or state audit. A finding is not an enforcement action against any named party and does not establish that any law was broken.
PROPOSED RULE
An agency proposal, open or closed to comment. It creates no obligation until finalized with an applicable compliance date.
FINAL RULE
A rule with legal effect. The record carries the citation, the effective date, and whether any part is stayed or enjoined.
A new development never overwrites an older one. When a charge is dismissed, a settlement is entered, or a rule is finalized, the disposition is added to the existing record as a dated entry and the record’s lifecycle state changes. Nothing is deleted, and no URL disappears. Every record therefore carries one lifecycle state:
State
Meaning
CURRENT
The authoritative present state of this subject.
EFFECTIVE
In force now, with an effective date.
PROPOSED
Issued but not binding. Carries comment status and any proposed compliance date.
FINAL
Adopted with legal effect, with citation and effective date.
SUPERSEDED
Replaced by a later state. Never shown without naming its successor.
HISTORICAL
Accurate as of its date, retained for the record, not the present state.
CORRECTED
Factually amended; the entry states its current content.
Published records
The records below carry their instrument, the body that acted, the action type and the current state, each read at the authority that issued it. The standing record set — corporate control of practice, payment integrity, licensure, data and AI, agency power — follows in the regulatory and litigation record. Defendant counts, loss figures and penalty amounts are stated only from the issuing authority’s own document.
DEVICE SAFETYEARLY ALERT — FIRM RECALL IN PROGRESS
Intraosseous needle sets recalled after reports the stylet can lock during insertion
United States — FDA, Center for Devices and Radiological Health. Five BD powered-driver intraosseous needle kits (15Ga, 15–55mm) were manufactured with out-of-tolerance dimensions, which can allow the obturator to rotate and lock into the needle hub during insertion. FDA reports that as of July 22 BD had reported 45 serious injuries and four deaths associated with the issue. Affected lots were distributed between September 30, 2024 and June 12, 2026; the powered driver is not affected.
ExposureThe failure occurs at insertion, in the settings where intraosseous access is used at all — out-of-hospital cardiac arrest and severe trauma. Affected stock is to be destroyed rather than returned, which makes this an inventory task with a clinical deadline.
For physiciansA needle already placed and functioning needs no further step, and one already used and removed needs no follow-up. FDA states expressly that an unsuccessful intraosseous attempt does not exhaust vascular access: further peripheral attempts or central access remain available on clinical judgement and local protocol.
What it does not establishAn early alert is FDA notifying the public of a potentially high-risk issue while it is still reviewing information. A Class I designation for this 2026 event is not posted in FDA’s device-recall database at the date of reading and is not asserted here; the separately classified 2022 BD intraosseous recall is a different event. The injury and death counts are reports made to FDA, not adjudicated causation.
REGULATORY POLICY DEVELOPMENTDISCUSSION PAPER — OPEN FOR FEEDBACK
FDA discussion paper on regulating generative-AI medical devices
United States — FDA, Center for Devices and Radiological Health, Digital Health Center of Excellence. A two-axis risk-assessment framework, a premarket approach built on competency assessment (non-clinical benchmarking followed by clinical confirmation), risk-proportionate postmarket monitoring options, and considerations for foundation models and agentic systems. Each section asks questions rather than setting expectations.
ExposureIf the competency model is carried forward, the evidence a vendor must hold before a generative tool reaches a clinic changes shape — and so does what an institution can be expected to have checked before deploying one.
For physiciansThe comment window is the only stage at which a clinician’s account of how these tools actually behave in practice enters the record. It closes 19 October 2026.
What it does not establishNot a rule, not draft guidance, not final guidance. FDA states it is not proposing or implementing policy and is not communicating regulatory expectations, and the paper does not address whether the approaches discussed fall within existing legal authority. No duty arises from this record.
United States — CMS. CMS-1848-P, 91 FR 43842. Placed on public display July 14, 2026, published July 16, 2026; comment period closes at close of business September 14, 2026. Finalized policies would generally take effect January 1, 2027. No obligation arises from this record until a final rule issues.
ExposureA split conversion factor converts alternative-payment participation from a strategic preference into a financial fork. An efficiency adjustment applied to work RVUs redistributes income across specialties without any change in what the physician does.
For physiciansThe comment window is the only period in which a physician's objection can change the rule. It closes 14 September 2026. After that the argument moves to litigation, where the standard of review is far less favourable.
Interoperability Standards and Prior Authorization for Drugs (CMS-0062-P)
United States — CMS / HHS. Would extend the electronic prior-authorization framework built by CMS-0057-F to drugs under both the medical and pharmacy benefit, require impacted payers to report API endpoints and usage metrics, and adopt certain HL7 FHIR standards under HIPAA Administrative Simplification. Most proposed provisions carry an October 1, 2027 compliance date. Proposed only; the October 2027 dates are not current duties.
Dated record of government action relevant to practising physicians, 1 January 2026 through 30 August 2026, newest first. Each entry names its instrument, the body that acted, its action type, exactly one lifecycle state, the date, the primary source it was read at, and the date of that reading. Allegations are marked as allegations; proposals are marked as proposals.
Jurisdictions in this record: California · United States · Canada · United Kingdom · European Union · Australia. A development is recorded where the acting body sits; where a foreign instrument reaches a Californian practice, the record says how.
Swipe the table sideways for the remaining columns
Government action relevant to physicians, newest first — 62 records across 8 jurisdictions
CMS proposes to replace the 6 percent provider-tax threshold with state-specific ceilings
CMS-2452-P, 91 FR (2026-14897) — Medicaid Program; Amending the Indirect Hold Harmless Threshold of Health Care-Related Taxes; released 21 July 2026, published 23 July 2026
· verified
What happenedThe rule would implement section 71115 of Public Law 119-21 by replacing the long-standing 6 percent indirect hold-harmless threshold with thresholds based on taxes enacted and imposed as of 4 July 2025, effective 1 October 2026, with a phase-down for most permissible classes in Medicaid expansion states from 1 October 2027. It would also add services of health insurers as a new permissible class and create new reporting requirements. Comments are due 21 September 2026. The CMS Office of the Actuary estimates the rule would reduce federal expenditures by $246 billion over ten years.
What it changes for physiciansThis is a financing rule with clinical consequences: provider taxes fund a large share of the non-federal Medicaid share, and a state that loses that revenue adjusts provider rates, eligibility processing, or managed-care capitation — not its statutory obligations. For a physician seeing Medi-Cal patients, the exposure is rate and access pressure two budget cycles out, not a compliance duty.
What it does not doProposed. The 1 October 2026 statutory date belongs to section 71115, not to this rule; nothing in the proposal binds a state or a provider until a final rule issues.
LEGISLATION IN PROGRESSPROPOSEDUnited States · House Committee on Ways and Means
Ways and Means advances the Medicare Advantage prior-authorization bill to the full House
H.R. 3514, Improving Seniors' Timely Access to Care Act; full-committee markup, 15 July 2026
· verified
What happenedThe committee marked up a health package including H.R. 3514 and reported it out; the bill advances to the full House. As introduced, it would require an electronic prior-authorization programme and enrollee-protection standards for plan years beginning on or after 1 January 2028, with transparency requirements from 1 January 2027.
What it changes for physiciansThis is the legislative track running alongside the CMS interoperability rules. If it passes in this form, the API duties CMS built by rule acquire a statutory floor and a real-time-decision definition that a rule alone can revise.
What it does not doA reported bill is not law. Nothing in it binds any plan today, and committee approval does not schedule a floor vote.
ADMINISTRATIVE ENFORCEMENTCURRENTCalifornia · Department of Managed Health Care
DMHC fines Blue Shield of California $300,000 over denied newborn-care payments
DMHC enforcement action announced 23 June 2026; Knox-Keene Health Care Service Plan Act
· verified
What happenedThe Department announced a $300,000 administrative penalty against Blue Shield of California for denying payments for newborn care.
What it changes for physiciansNewborn care is the recurring pattern in this line of enforcement: the infant is a new enrollee whose eligibility posts after the encounter, so the claim is denied on enrollment grounds for care the plan must cover. A denial in that shape is a plan-side defect worth escalating rather than writing off.
What it does not doAn administrative penalty against a plan is not a finding about any physician or any individual claim, and it does not itself reopen denied claims.
CRIMINAL CHARGECURRENTUnited States · Department of Justice
2026 National Health Care Fraud Takedown: 455 defendants charged
DOJ 2026 National Health Care Fraud Takedown, announced 23 June 2026
· verified
What happenedDOJ announced charges against 455 defendants, including 90 doctors and other licensed medical professionals, in schemes involving over $6.5 billion in alleged false claims. Cases were brought in 56 federal districts across 45 states and territories, with all 50 state Medicaid Fraud Control Units participating, and over $182 million in assets seized. Alongside the charges, CMS suspended 1,079 providers and revoked billing privileges for 1,403.
What it changes for physiciansThe administrative half is the part physicians underestimate. A payment suspension or revocation lands before any adjudication and does not wait for a plea, a verdict, or a licensing decision — which is why the CMS numbers, not the defendant count, are the operational risk.
What it does not doEvery charge is an allegation. No finding of guilt exists until conviction or plea, and dispositions will be added to this record as they issue rather than replacing it.
AUDIT / OVERSIGHT FINDINGCURRENTUnited States · HHS Office of Inspector General
OIG finds post-acute prior-authorization denial rates far above the all-services rate
OEI-09-24-00331 (skilled nursing facilities) and OEI-09-24-00330 (long-term care hospitals and inpatient rehabilitation facilities), completed 8 June 2026, posted 11 June 2026
· verified
What happenedReviewing June 2024 data from the 19 largest Medicare Advantage organizations, OIG found 12 percent of SNF admission requests denied, with plan-level rates from 0.4 to 23 percent; 18 percent of SNF denials were appealed, and 95 percent of appealed denials were overturned in the enrollee's favour. Denial rates reached 65 percent for long-term care hospital requests and 54 percent for inpatient rehabilitation, with the three largest organizations among the highest.
What it changes for physiciansA 95 percent overturn rate is an argument about initial determinations, not about appeals working. For the discharging physician it means a denial of post-acute placement is worth appealing on the clinical record you already have, and that the delay itself — days in an acute bed — is the harm to document.
What it does not doAn audit finding is not an enforcement action and establishes no violation by any named plan. OIG's data cannot separate denials that should never have issued from approvals granted on later documentation.
PROPOSED REGULATIONPROPOSEDCalifornia · Office of Health Care Affordability (HCAI)
OHCA proposes the regulations that implement AB 1415's notice regime
Proposed revisions to the material change transaction and cost-and-market-impact-review regulations (Cal. Code Regs., tit. 22, div. 7, ch. 11.5), text dated May 2026, implementing AB 1415 (Ch. 641, Stats. 2025)
· verified
What happenedOHCA published proposed regulatory text for informal comment and accepted comments until 11 June 2026. The text extends the notice framework to noticing entities — private equity groups, hedge funds, newly created entities and certain management services organizations — and carries the 90-day advance filing requirement across to them. Until regulations are enacted, OHCA's own FAQ states that noticing entities must at a minimum provide written notice under Health and Safety Code section 127507(c)(2)(A).
What it changes for physiciansThis answers the question the statute left open on 1 January: an MSO transaction closing now is already inside the notice duty, and the interim standard is written notice rather than the full filing package. Waiting for final regulations is not a compliance position.
What it does not doProposed and, on the record read, not adopted. The definitions and ownership thresholds in the draft may change before adoption, and no compliance date attaches to the draft itself.
MHRA publishes the draft Medical Devices (Amendment) Regulations 2026 for Great Britain
Draft Medical Devices (Amendment) Regulations 2026, notified on the World Trade Organisation portal 8 May 2026; stakeholder impact survey closed 19 June 2026
· verified
What happenedThe draft statutory instrument sets new pre-market requirements for medical devices and in vitro diagnostics entering the Great Britain market, replacing requirements carried over from the retained EU directives. MHRA invited comment from WTO members and, separately, from industry, approved bodies, healthcare providers and patients through a survey that closed at 23:59 on 19 June 2026.
What it changes for physiciansFor a clinician the consequence is downstream and practical: an instrument that changes classification and conformity assessment changes which devices and diagnostic software reach a British clinic, and on what evidence. Healthcare providers were named as consultees, which means the clinical view of a device's real-world performance was solicited at the drafting stage rather than after adoption.
What it does not doA draft statutory instrument. It creates no duty, and adoption requires Parliament; the timetable reported for adoption and entry into force is not part of the notified draft and is not verified here.
REGULATIONEFFECTIVEEuropean Union · European Commission
Uniform procedural requirements imposed on notified bodies under MDR and IVDR
Commission Implementing Regulation (EU) 2026/977 — uniform requirements for conformity assessment and notified bodies (MDR/IVDR, Annex VII), adopted May 2026
· verified
What happenedThe Implementing Regulation sets standardised procedural requirements for the conformity assessment activities of notified bodies under the Medical Devices Regulation and the In Vitro Diagnostic Regulation. It sits alongside, and is separate from, the Commission's targeted simplification proposal for MDR and IVDR published on 16 December 2025 (COM(2025) 1023 final), which remains in the ordinary legislative procedure before the Parliament and Council.
What it changes for physiciansCertification delay is the mechanism by which European device rules reach a clinic: a diagnostic or software device that cannot get through a notified body does not arrive. Standardising quotation, timeline and audit practice is aimed at that bottleneck, and it is in force now, unlike the larger revision.
What it does not doAn implementing regulation binds notified bodies, not clinicians, and it does not change the substantive safety and performance requirements of MDR or IVDR. The December 2025 simplification proposal is a proposal only; nothing in it applies. The exact adoption date within May 2026 is not verified here.
Health Canada publishes pre-market guidance for machine-learning-enabled medical devices
Health Canada, Pre-market guidance for machine learning-enabled medical devices (Class II–IV), April 2026
· verified
What happenedThe guidance sets Health Canada's expectations for machine-learning-enabled devices: the medical purpose must be stated for any Class II, III or IV device; predetermined change control plans provide a route to pre-authorise planned model changes that address a known risk; and manufacturers are expected to apply SGBA Plus, collecting and analysing disaggregated data on sub-populations across training, test and clinical data. Health Canada adopts the IMDRF terms and definitions for these devices.
What it changes for physiciansThe disaggregated-data expectation is the part a physician can use. A device authorised in Canada should be able to say how it performed in the populations a clinic actually serves, and the guidance makes that a documented submission element rather than a courtesy.
What it does not doGuidance states current thinking and is not binding law; it imposes no new statutory obligation and may be revised. Dated April 2026 on the departmental page; the exact publication day is not verified here.
TGA guidance: AI is regulated by intended purpose, including generative clinical decision support
TGA guidance, Artificial intelligence (AI) and medical device software regulation, updated February 2026
· verified
What happenedThe guidance states that regulation is triggered by the manufacturer's intended purpose rather than by the presence of AI, and it names clinical decision support tools that use generative AI to give diagnostic or treatment recommendations as regulated devices. Devices must be included in the Australian Register of Therapeutic Goods unless excluded or exempt, and synthetic data will generally not substitute for clinical data in meeting clinical evidence requirements.
What it changes for physiciansIntended purpose is the operative concept, so a tool marketed as an assistant is regulated on what it is for, not what it is called. Where a practice deploys a generative tool for a purpose outside its registered intended purpose, the guidance's own remedy is to cease supply or revise the purpose and re-submit — which makes off-label deployment the deploying organisation's exposure.
What it does not doGuidance interprets the Therapeutic Goods Act framework; it is not itself legislation. The exact date of the February 2026 update, and the listing of software as a medical device among the TGA's stated compliance priorities for 2026–2027, are not verified here.
ADMINISTRATIVE ENFORCEMENTCURRENTCalifornia · Department of Managed Health Care
DMHC fines Health Net plans $1.3 million for mishandling provider payment disputes
DMHC enforcement action announced 4 February 2026; Knox-Keene Act provider dispute resolution requirements
· verified
What happenedThe Department announced penalties totalling $1.3 million against Health Net plans for mishandling provider payment disputes.
What it changes for physiciansProvider dispute resolution has acknowledgment and resolution deadlines, and a plan's pattern of missing them is itself the violation — separate from whether any individual claim was payable. A practice that documents dispute dates is documenting the element the Department enforces on.
What it does not doA penalty against a plan resolves no individual dispute and makes no finding about any provider's billing. The per-plan allocation of the total was not read at source.
Consolidated Appropriations Act, 2026 extends Medicare telehealth flexibilities through 2027
H.R. 7148, Consolidated Appropriations Act, 2026 (119th Cong.), signed 3 February 2026
· verified
What happenedThe Act funds federal departments for the remainder of FY2026 and extends expiring programmes and authorities, including the Medicare telehealth flexibilities that had lapsed days earlier. The extension runs through 31 December 2027 and was applied retroactively across the gap.
What it changes for physiciansGeographic and originating-site relief, the expanded practitioner list, audio-only coverage and the deferral of the in-person requirement for tele-behavioural care all continue — but on a date certain, not permanently. Any 2028 schedule built on them is built on an authority that expires first.
What it does not doAn appropriations extension is not permanence. The same provisions have now lapsed and been restored twice in four months.
AUTHORITY LAPSEHISTORICALUnited States · Congress / CMS
Medicare telehealth flexibilities lapse for three days
Expiry of the extension enacted by the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (H.R. 5371), signed 12 November 2025, which carried the flexibilities to 30 January 2026; gap closed retroactively by H.R. 7148
· verified
What happenedThe extension in force through 30 January 2026 expired, and the flexibilities lapsed until the 3 February 2026 Act restored them retroactively.
What it changes for physiciansClaims for services furnished in the gap were payable in the end, but only after the fact. The operational lesson is the one practices keep re-learning: hold rather than cancel, because a retroactive fix cannot recreate a cancelled appointment.
What it does not doRecorded as historical: accurate as of its date, superseded in effect by the 3 February statute. The record states the lapse and its dates, not a pinpoint section designation within H.R. 5371.
ADMINISTRATIVE ENFORCEMENTCURRENTCalifornia · Department of Managed Health Care
DMHC fines Anthem Blue Cross $15 million over member-complaint failures
DMHC enforcement action announced 30 January 2026; Knox-Keene Act grievance and complaint requirements
· verified
What happenedThe Department announced a $15 million penalty against Anthem Blue Cross for what it described as longstanding and widespread failures in handling member complaints.
What it changes for physiciansIt is the largest California plan penalty of the year to date and it is about grievance handling, not medical necessity. Where a patient's grievance goes unanswered, the physician's clinical record is often the only contemporaneous account of the request — which is what makes the chart the evidence in a complaint case.
What it does not doAn administrative penalty is not a judicial finding and does not establish that any particular enrollee's care was wrongly denied.
Telemedicine prescribing of controlled substances continues through 2026, on a temporary rule
Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications, 90 FR (2025-24123), published 31 December 2025; effective 1 January 2026 through 31 December 2026
· verified
What happenedDEA, jointly with HHS, extended the pandemic-era telemedicine prescribing flexibilities for a fourth time. A DEA-registered practitioner may prescribe a Schedule II–V controlled substance following a telemedicine encounter without a prior in-person evaluation, provided the conditions in the temporary rule are met. HHS announced the extension on 2 January 2026 and stated that it buys time to finalise the proposed Special Registration for Telemedicine.
What it changes for physiciansThe date is the whole point: this authority ends on 31 December 2026, and it is the fourth time it has been extended by temporary rule rather than replaced by a permanent framework. A practice that treats tele-prescribing of controlled substances as settled policy is scheduling into an authority with a fixed expiry and no successor in force.
What it does not doA temporary rule. It changes nothing about the requirement that prescriptions issue for a legitimate medical purpose by a licensed practitioner in compliance with federal and state law, and it does not create the special registration that would replace it.
CY 2026 Physician Fee Schedule takes effect with two conversion factors
CY 2026 Medicare Physician Fee Schedule final rule, 90 FR (2025-19787), effective 1 January 2026
· verified
What happenedFor the first time Medicare pays under two conversion factors: $33.5675 for qualifying participants in advanced alternative payment models and $33.4009 for everyone else. The rule also applied an efficiency adjustment of −2.5 percent to the work RVUs of non-time-based services and made virtual direct supervision permanent.
What it changes for physiciansA headline increase and a code-level cut arrive together, so the net effect depends entirely on a practice's mix: procedural, non-time-based work absorbs the efficiency adjustment while time-based codes do not. The APM differential also converts model participation from a bonus question into a rate question.
What it does not doIn force. The 2.5 percent statutory increase inside the conversion factors is a one-year addition, not a new baseline.
Things a reader may assume changed in 2026, which did not. Each is verified to the instrument's own record, and each is a reason not to plan against a headline. As of .
PROPOSEDHIPAA Security Rule overhaul
The notice of proposed rulemaking published in the Federal Register on 6 January 2025 (comments closed 7 March 2025) has not been finalised. HHS states that while the rulemaking is under way, the current Security Rule remains in effect. Encryption of ePHI, multi-factor authentication and the other headline controls are proposals, not duties.
The Commission's simplification proposal of 16 December 2025 is before the Parliament and Council. Nothing in it — including the proposed treatment of AI-enabled devices under sectoral rules rather than the AI Act's high-risk regime — applies today.
The draft Medical Devices (Amendment) Regulations 2026 are a draft statutory instrument. UKCA and the existing recognition arrangements continue until Parliament acts.
Swipe the table sideways for the remaining columns
Dates already fixed beyond the window — 12 in the record. Published so a reader can see what is scheduled without treating a schedule as a present duty.
Date
Jurisdiction
What is scheduled
Source
United States
NPDB merges One-Time Query and Continuous Query into NPDB Query
Every entry names its forum or instrument, its posture, the operative authority, and the exposure it actually creates. Postures are not blurred: an amicus brief is not a holding, a settlement without admission is not an adjudication, and a proposed rule binds nobody.
Postures used in this set
Enacted & effective
Law now. Compliance is not optional and the effective date has passed.
Proposed
Published for comment. States an agency's intention and binds nobody until final.
Settled
Resolved by agreement. Frequently without any admission of liability — which limits its precedential weight while leaving its practical signal intact.
Pending
Live before a court or agency. The outcome is not yet law.
Agency position
An enforcement view stated in a brief, guidance or FAQ. Persuasive, not binding — but it is the view you will be litigating against.
Corporate control of practice
Enacted & effectiveEFFECTIVECalifornia
SB 351: private-equity control of clinical judgment becomes a statutory violation with a named enforcer
Senate Bill 351, Ch. 409, Stats. 2025 — effective 1 January 2026
Signed · Effective
HoldingCalifornia codified its corporate-practice doctrine as applied to private-equity groups and hedge funds holding interests in physician and dental practices. The statute draws an express line around clinical decision-making, billing determinations and clinical staffing, and it gives the Attorney General injunctive relief, equitable remedies and attorney's fees.
ExposureTwo things changed that matter to a practising physician. First, the conduct is now named in statute rather than inferred from a line of authority, which makes it far easier to plead. Second, the Attorney General has an express remedy and a fee award — an enforcement economics change, not merely a doctrinal one. Continued billing to a government payor from a non-compliant structure carries derivative exposure under the California and federal False Claims Acts, subject to the materiality requirement.
For physiciansIf your practice sits inside an MSO structure, the question is no longer whether the paperwork recites physician control. It is whether the management agreement gives anyone the practical ability to override a clinical decision, set a billing policy, or determine staffing on a productivity basis. Read the agreement for those three powers specifically.
Carbon Health: the friendly-PC model drew a structural remedy and individual liability
California Attorney General settlement with Carbon Health Technologies, Inc., its affiliated professional medical corporations, and its co-founder and former chief executive
Announced
HoldingA first-of-its-kind resolution of alleged corporate-practice, false-advertising, consumer-contracting and billing violations: $4.5 million in combined penalties and a required corporate reorganization of the friendly-PC arrangement. The judgment was submitted as a compromise of disputed claims, without trial and without any admission of liability.
ExposureThe remedy is the signal. A penalty is a cost of doing business; a mandated reorganization is a finding about the model itself. Naming a founder and former chief executive individually removes the assumption that corporate-practice exposure stops at the entity.
For physiciansPhysician-owners of affiliated professional corporations should understand that they are not merely nominal parties to this structure. Where the state seeks reorganization, the practice entity is what gets reorganized — and the physician of record is the person holding the licence it depends on.
Art Center Holdings: the Attorney General's position on the power to replace a physician-owner
The Attorney General’s brief was filed . The California Medical Association filed a competing brief on .
Amicus curiae brief of the California Attorney General in Art Center Holdings, Inc. v. WCE CA Art, LLC (California Court of Appeal)
Filed
HoldingThe Attorney General urged affirmance of a trial-court holding that contractual provisions permitting a management services organization to replace a practice's physician-owner violate the corporate-practice prohibition. The brief is careful: it concedes that not every MSO-PC relationship confers impermissible control, and that the analysis is a totality of the circumstances. It nevertheless identifies without-cause replacement rights as among the highest-risk features of a California structure.
ExposureAn amicus brief is not a holding, and this one should not be cited as though it were. Its value is diagnostic: it tells you which contractual term the enforcing authority will reach for first.
For physiciansFind the removal provision in your management agreement. If a non-physician party can replace the physician-owner without cause, that is the clause the state has publicly identified as its primary target.
Aspen Dental: corporate practice paired with a false-advertising count
California Attorney General settlement with Aspen Dental Management, Inc.
Announced
HoldingAlleged violations of the prohibition on the corporate practice of dentistry together with false and misleading advertising, resolved for $2 million in penalties and $300,000 in patient restitution, with injunctive terms and subject to court approval.
ExposureThe pleading strategy is worth noting on its own. Pairing a corporate-practice count with a consumer-protection count gives the state a second, easier theory and a restitution mechanism that a licensing action cannot reach.
For physiciansAdvertising copy that implies a professional relationship the structure does not actually support is a second front. Review how the practice describes who is treating the patient.
AB 1415: management organizations enter the pre-transaction notice regime
Assembly Bill 1415, Ch. 641, Stats. 2025 — effective 1 January 2026
Effective
HoldingManagement services organizations were added to the pre-transaction notice requirements administered by the Office of Health Care Affordability.
ExposureTransactions that previously closed without state visibility now surface before completion. Notice regimes do not prohibit; they create a record, a delay, and an opportunity for the state to object — which changes deal structuring more than any penalty would.
For physiciansIf your practice is being acquired or reorganized, ask directly whether a notice filing was made. Its absence is itself a compliance question.
The derivative theory: corporate-practice violations as False Claims Act exposure
31 U.S.C. §§ 3729–3733 (federal False Claims Act); California False Claims Act, Gov. Code § 12650 et seq.; Cal. Bus. & Prof. Code §§ 2052, 2264
Current exposure
HoldingA regulatory violation can support False Claims Act liability, but only where it is material — the payor must have the authority, ability and inclination to deny payment on that basis. Corporate-practice violations reach the Act through that door, and frequently overlap with anti-kickback and physician self-referral exposure.
ExposureMateriality is the whole argument, and it is where these cases are won and lost. A relator will plead the violation as a condition of payment; the defence will contest whether the payor would in fact have refused. Nothing about the theory is automatic.
For physiciansAnyone with visibility into a non-compliant arrangement — physicians, administrators, billing staff, MSO employees — is a potential relator. That is a structural fact about the exposure, not a comment on any individual.
Prior authorization becomes an API obligation and a published metric
CMS-0057-F — Interoperability and Prior Authorization final rule
Decision timeframes and denial reasons · Four FHIR APIs required
HoldingExpedited decisions within 72 hours, standard decisions within seven calendar days, a specific reason for every denial, public reporting of authorization metrics, and four required FHIR interfaces. The rule binds Medicare Advantage organizations, Medicaid and CHIP managed care plans, state fee-for-service programs, and qualified health plan issuers on the federally facilitated exchanges.
ExposurePublication is the enforcement mechanism. Once denial rates and turnaround times are public per payer, the comparison itself does work that no individual appeal could.
For physiciansBecause the rule reaches Medicaid and CHIP managed care, it applies to Medi-Cal managed care and not only to Medicare Advantage. The decision clock and the duty to give a specific reason are enforceable now.
California licensure discipline: where the procedural leverage actually sits
Cal. Gov. Code § 11500 et seq. (Administrative Procedure Act); Cal. Bus. & Prof. Code § 2220 et seq.
Current law
HoldingA Medical Board accusation is heard by an administrative law judge at the Office of Administrative Hearings. Discovery is narrower than in civil litigation, the licence is taken only on clear and convincing proof to a reasonable certainty, and the judge's decision is proposed — the Board panel decides.
ExposureThe decisive moments are earlier than most physicians expect: the written response to the complaint letter, the decision whether to submit to an interview, and the notice of defence. By the time an accusation is public, the record has largely been built.
For physiciansTreat the first letter as the beginning of a formal proceeding, because it is. The standard of proof is favourable; the procedural timetable is not.
HoldingHigh-risk obligations moved to December 2027. The Article 50 transparency duties were not deferred and began applying on 2 August 2026: a person interacting with an AI system must be told.
ExposureThe deferral was widely reported as a pause. It was not. A health system relying on the later date is already out of compliance on the part of the regulation that touches patients directly.
For physiciansRelevant to any US institution operating in Europe, and a useful comparator for anyone arguing about disclosure duties domestically — the transparency obligation was severable from the risk-classification scheme, and was severed.
AI-enabled devices and the change-control question
FDA digital health framework — clinical decision support guidance; AI-enabled device list; predetermined change control plans
Current framework
HoldingLifecycle management and predetermined change-control plans remain the organising framing for AI-enabled devices, with future list versions intended to identify devices built on foundation models and large language models.
ExposureGuidance is not law, but it is what a submission is judged against. The operative question for a clinician is not whether a tool was cleared, but whether it may change after clearance without a further review.
For physiciansBefore relying on an AI tool, ask whether it has a predetermined change control plan and what that plan permits without new review. A tool that may silently alter its own behaviour is a different instrument from the one that was validated.
After Loper Bright: agency health rules defended without deference
Loper Bright Enterprises v. Raimondo, 603 U.S. 369 (2024), overruling Chevron U.S.A. Inc. v. NRDC
Decided
HoldingCourts no longer defer to an agency's reasonable interpretation of an ambiguous statute; they exercise independent judgment on the meaning of the statutory text.
ExposureEvery substantial health rule now rests on how well its statutory authority was drafted rather than on how reasonable the agency's reading is. That cuts in both directions — the same reasoning that unsettles a rule a physician dislikes unsettles one a physician relies on.
For physiciansA rule being challenged is not a rule being suspended. Comply with what is in force while it is in force, and watch for a stay rather than for a filing.
Medical Board actions: what gets recorded, and how
Board actions are eligible for the weekly record for events from onward. Licensure discipline is the category most easily reported wrongly, because the Board publishes documents at four different stages and only two of them are discipline. The rule below is published so a reader can see what a Board entry here does and does not assert.
Only actions the Board itself has posted: accusation, decision, suspension order, public letter of reprimand.
The document type is named in the record; an accusation is labelled an allegation and never reported as discipline.
Aggregate counts only from a Board report or agenda item, never assembled by counting website entries.
Petitions to revoke probation and interim suspension orders are recorded as pending, with their disposition appended when it issues.
Public letters of reprimand are removed from the Board's site ten years after the effective date under Bus. & Prof. Code § 2027; a record citing one notes the removal date.
The boundaries of the ledger are part of the record. Each limit below is a statement about scope, not a hedge about accuracy: within its scope every entry names its instrument, its jurisdiction, its state and the primary source it rests on.
Individual physician discipline. Medical Board accusations and decisions are not listed here as a class. The Board’s 19–21 August 2026 meetings appear as a public-meeting record; actions the Board takes will be added as dated entries once they exist in a Board-posted decision or approved minutes.
Actions outside the six jurisdictions listed. California, the United States, Canada, the United Kingdom, the European Union and Australia. An action in a seventh jurisdiction is not absent because it does not matter; it is absent because this ledger does not claim to survey it.
Day-precision dates on a small number of foreign instruments. Where an authority publishes a month rather than a day — Health Canada’s machine-learning guidance and the TGA’s artificial-intelligence guidance among them — the entry carries the month and does not invent a day.
Figures an authority has not published. Defendant counts, alleged-loss totals and programme-integrity savings appear only where the issuing body states them. Where they do not, the entry describes the action without them.
Anything an aggregator reported and an authority has not. A secondary report is a reason to look for the instrument. It is never the citation, and an item that cannot be read at the authority does not appear here at all.
Classification is never collapsed. An audit finding is not fraud. A charge is not a conviction. A settlement is not an admission. A proposal is not law, guidance is not statute, and a safety alert is not necessarily a recall. Each entry carries the action type the issuing body used.
Policy signals
The ledger stays documentary. But where a pattern of enforcement exposes a structural gap, the gap is analysed in the Reform Agenda — as a labelled KPSGILL proposal, never as part of the record. Three patterns currently cross-reference:
Plan conduct enforced case by case — DMHC fines on complaint-handling and payment failures arrive after the interruption of care. The model payer standard proposes the standing rule the fines currently substitute for.
Laboratory failures reached as fraud, years later — payment-integrity recoveries follow claims already paid on known-failed processes. The payment-integrity proposal moves the lever before payment.
Corporate-practice actions without an operative conduct list — settlements and amicus positions carry the doctrine case by case. The model regulation enumerates the levers so enforcement has a definition to apply.
